Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Akero To Contact Him Directly To Discuss Their Options New York, ...

Stockholders' Equity: Grew to $846.25 million, up from $535.31 million at the end of the previous year.

Statistically significant week 96 results from the Phase 2b HARMONY study of EFX in patients with pre-cirrhotic MASH reported ...

Q1 GAAP EPS of -$0.90 beats by $0.05. Akero's cash, cash equivalents and short-term marketable securities as of March 31, ...

Analyst Ed Arce of H.C. Wainwright maintained a Buy rating on Akero Therapeutics (AKRO – Research Report), retaining the price target of ...

Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Akero To Contact Him Directly To Discuss Their Options ...

May 14, 2024) - The law firm of Kessler Topaz Meltzer & Check, LLP ( informs investors that a securities class action ...

May 10, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by ...

Pomerantz LLP announces that a class action lawsuit has been filed against Akero Therapeutics, Inc. (“Akero” or the “Company”) (NASDAQ: AKRO). Such ...

On Tuesday, Evercore ISI adjusted its price target for Akero Therapeutics (NASDAQ:AKRO), a biotechnology company focused on developing treatments for non-alcoholic steatohepatitis (NASH).

Warning! GuruFocus has detected 3 Warning Signs with AKRO. Akero Therapeutics Inc (NASDAQ:AKRO) released its 8-K filing on May 10, 2024, detailing its financial results for the first quarter of 2024.